Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization

English version České info

As vaccination, immunoprophylaxis and immunotherapies are becoming increasingly feasible approaches to combat HIV/AIDS, understanding the activity of relevant anti-HIV antibodies is crucial. Antibody 10E8 defines a key vulnerability on the envelope spikes of a vast majority of HIV isolates but mechanisms of resistance to this neutralizing antibody are incompletely understood. Our findings show how partial neutralization of HIV can occur through apparent partial occupancy by 10E8 of HIV spikes that is accompanied by specific, antibody mediated effects on spike stability, infectivity and sensitivity to various inhibitors of HIV. We reveal a previously unappreciated mechanism of spike-antibody recognition where consequences on viral infectivity by 10E8 binding are dependent on interactions between subunits of the virion spike that modulate its stability and recognition properties. HIV vaccine development and immunoprophylaxis involving 10E8-like antibodies and their target, the gp41 MPER, may have to consider functional relationships involving the MPER and antibody occupancy at the base of trimeric spikes.

Vyšlo v časopise: Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization. PLoS Pathog 10(7): e32767. doi:10.1371/journal.ppat.1004271
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004271

Souhrn

Zdroje

1. BurtonDR, AhmedR, BarouchDH, ButeraST, CrottyS, et al. (2012) A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 12: 396–407.

2. MascolaJR, HaynesBF (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254: 225–244.

3. KleinF, MouquetH, DosenovicP, ScheidJF, ScharfL, et al. (2013) Antibodies in HIV-1 vaccine development and therapy. Science 341: 1199–1204.

4. AgrawalN, LeamanDP, RowcliffeE, KinkeadH, NohriaR, et al. (2011) Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1). PLoS One 6: e21339.

5. LayneSP, MergesMJ, DemboM, SpougeJL, ConleySR, et al. (1992) Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 189: 695–714.

6. DooresKJ, BurtonDR (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84: 10510–10521.

7. BonomelliC, DooresKJ, DunlopDC, ThaneyV, DwekRA, et al. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6: e23521.

8. CrooksET, TongT, OsawaK, BinleyJM (2011) Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol 85: 5825–5839.

9. LeamanDP, ZwickMB (2013) Increased functional stability and homogeneity of viral envelope spikes through directed evolution. PLoS Pathog 9: e1003184.

10. HuangJ, OfekG, LaubL, LouderMK, Doria-RoseNA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406–412.

11. GachJS, LeamanDP, ZwickMB (2011) Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. Curr Top Med Chem 11: 2997–3021.

12. Montero M, van Houten NE, Wang X, Scott JK (2008) The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 72: 54–84, table of contents.

13. ZwickMB, BurtonDR (2007) HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr HIV Res 5: 608–624.

14. SchibliDJ, MontelaroRC, VogelHJ (2001) The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry 40: 9570–9578.

15. SunZY, OhKJ, KimM, YuJ, BrusicV, et al. (2008) HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28: 52–63.

16. HuarteN, AraujoA, ArranzR, LorizateM, QuendlerH, et al. (2012) Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity. PLoS One 7: e52740.

17. BrunelFM, ZwickMB, CardosoRM, NelsonJD, WilsonIA, et al. (2006) Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol 80: 1680–1687.

18. OfekG, TangM, SamborA, KatingerH, MascolaJR, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78: 10724–10737.

19. PejchalR, GachJS, BrunelFM, CardosoRM, StanfieldRL, et al. (2009) A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol 83: 8451–8462.

20. CardosoRM, ZwickMB, StanfieldRL, KunertR, BinleyJM, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22: 163–173.

21. JulienJP, CupoA, SokD, StanfieldRL, LyumkisD, et al. (2013) Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer. Science. 342(6165): 1477–83.

22. LyumkisD, JulienJP, de ValN, CupoA, PotterCS, et al. (2013) Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer. Science. 342: 1484–1490.

23. ZwickMB, KomoriHK, StanfieldRL, ChurchS, WangM, et al. (2004) The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 78: 3155–3161.

24. SchererEM, LeamanDP, ZwickMB, McMichaelAJ, BurtonDR (2010) Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A 107: 1529–1534.

25. AlamSM, MorelliM, DennisonSM, LiaoHX, ZhangR, et al. (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A 106: 20234–20239.

26. BuzonV, NatrajanG, SchibliD, CampeloF, KozlovMM, et al. (2010) Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog 6: e1000880.

27. GuenagaJ, WyattRT (2012) Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. PLoS Pathog 8: e1002806.

28. ZhuJ, OfekG, YangY, ZhangB, LouderMK, et al. (2013) Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci U S A 110: 6470–6475.

29. ChenJ, FreyG, PengH, Rits-VollochS, GarrityJ, et al. (2013) Mechanism of HIV-1 Neutralization by Antibodies Targeting a Membrane-Proximal Region of gp41. J Virol. 88: 1249–1258.

30. TranEE, BorgniaMJ, KuybedaO, SchauderDM, BartesaghiA, et al. (2012) Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 8: e1002797.

31. JulienJP, SokD, KhayatR, LeeJH, DooresKJ, et al. (2013) Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 9: e1003342.

32. YangX, KurtevaS, LeeS, SodroskiJ (2005) Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol 79: 3500–3508.

33. CrooksET, JiangP, FrantiM, WongS, ZwickMB, et al. (2008) Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 377: 364–378.

34. JulienJP, LeeJH, CupoA, MurinCD, DerkingR, et al. (2013) Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A 110: 4351–4356.

35. ChakrabartiBK, WalkerLM, GuenagaJF, GhobbehA, PoignardP, et al. (2011) Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol 85: 8217–8226.

36. LeamanDP, KinkeadH, ZwickMB (2010) In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J Virol 84: 3382–3395.

37. de RosnyE, VassellR, JiangS, KunertR, WeissCD (2004) Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 78: 2627–2631.

38. KleinJS, GnanapragasamPN, GalimidiRP, FoglesongCP, WestAPJr, et al. (2009) Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A 106: 7385–7390.

39. RuprechtCR, KrarupA, ReynellL, MannAM, BrandenbergOF, et al. (2011) MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 208: 439–454.

40. NelsonJD, KinkeadH, BrunelFM, LeamanD, JensenR, et al. (2008) Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377: 170–183.

41. KoshibaT, ChanDC (2003) The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J Biol Chem 278: 7573–7579.

42. DimitrovAS, JacobsA, FinneganCM, StieglerG, KatingerH, et al. (2007) Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 46: 1398–1401.

43. HamburgerAE, KimS, WelchBD, KayMS (2005) Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 280: 12567–12572.

44. EckertDM, ShiY, KimS, WelchBD, KangE, et al. (2008) Characterization of the steric defense of the HIV-1 gp41 N-trimer region. Protein Sci 17: 2091–2100.

45. MaoY, WangL, GuC, HerschhornA, DesormeauxA, et al. (2013) Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A. 110(30): 12438–12443.

46. NelsonJD, BrunelFM, JensenR, CrooksET, CardosoRM, et al. (2007) An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 81: 4033–4043.

47. ZwickMB, JensenR, ChurchS, WangM, StieglerG, et al. (2005) Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 79: 1252–1261.

48. MonteroM, GulzarN, KlaricKA, DonaldJE, LepikC, et al. (2012) Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J Virol 86: 2930–2941.

49. NakamuraKJ, GachJS, JonesL, SemrauK, WalterJ, et al. (2010) 4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms. PLoS One 5: e9786.

50. GrayES, MoorePL, Bibollet-RucheF, LiH, DeckerJM, et al. (2008) 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol 82: 2367–2375.

51. CardosoRM, BrunelFM, FergusonS, ZwickM, BurtonDR, et al. (2007) Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol 365: 1533–1544.

52. LiuJ, DengY, DeyAK, MooreJP, LuM (2009) Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry 48: 2915–2923.

53. PerezLG, Zolla-PaznerS, MontefioriDC (2013) Antibody-dependent, FcgammaRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis. J Virol 87: 5287–5290.

54. BinleyJM, BanYE, CrooksET, EgginkD, OsawaK, et al. (2010) Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 84: 5637–5655.

55. LovingR, SjobergM, WuSR, BinleyJM, GaroffH (2013) Inhibition of the HIV-1 Spike by Single-PG9/16-Antibody Binding Suggests a Coordinated-Activation Model for Its Three Protomeric Units. J Virol 87: 7000–7007.

56. WalkerLM, PhogatSK, Chan-HuiPY, WagnerD, PhungP, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289.

57. FreyG, PengH, Rits-VollochS, MorelliM, ChengY, et al. (2008) A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A 105: 3739–3744.

58. BinleyJM, CayananCS, WileyC, SchulkeN, OlsonWC, et al. (2003) Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 77: 5678–5684.

59. FollisKE, LarsonSJ, LuM, NunbergJH (2002) Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state. J Virol 76: 7356–7362.

60. Munoz-BarrosoI, SalzwedelK, HunterE, BlumenthalR (1999) Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol 73: 6089–6092.

61. MedjahedH, PachecoB, DesormeauxA, SodroskiJ, FinziA (2013) The HIV-1 gp120 major variable regions modulate cold inactivation. J Virol 87: 4103–4111.

62. IngaleS, GachJS, ZwickMB, DawsonPE (2010) Synthesis and analysis of the membrane proximal external region epitopes of HIV-1. J Pept Sci 16: 716–722.

63. CaffreyM, KaufmanJ, StahlS, WingfieldP, GronenbornAM, et al. (1999) Monomer-trimer equilibrium of the ectodomain of SIV gp41: insight into the mechanism of peptide inhibition of HIV infection. Protein Sci 8: 1904–1907.

64. SalzwedelK, BergerEA (2009) Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer. Retrovirology 6: 75.

65. BlishCA, NguyenMA, OverbaughJ (2008) Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med 5: e9.

66. KhasawnehAI, LaumaeaA, HarrisonDN, Bellamy-McIntyreAK, DrummerHE, et al. (2013) Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41. Retrovirology 10: 44.

67. XuH, SongL, KimM, HolmesMA, KraftZ, et al. (2010) Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J Virol 84: 1076–1088.

68. FreyG, ChenJ, Rits-VollochS, FreemanMM, Zolla-PaznerS, et al. (2010) Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol 17: 1486–1491.

69. AndersonLJ, BinghamP, HierholzerJC (1988) Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 62: 4232–4238.

70. MartinezI, MeleroJA (1998) Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein. J Gen Virol 79 (Pt 9): 2215–2220.

71. KimM, SunZY, RandKD, ShiX, SongL, et al. (2011) Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol 18: 1235–1243.

72. BarouchDH, WhitneyJB, MoldtB, KleinF, OliveiraTY, et al. (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503: 224–228.

73. Cheng-MayerC, HomsyJ, EvansLA, LevyJA (1988) Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci U S A 85: 2815–2819.

74. RootMJ, KayMS, KimPS (2001) Protein design of an HIV-1 entry inhibitor. Science 291: 884–888.

75. BurtonDR, PyatiJ, KoduriR, SharpSJ, ThorntonGB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024–1027.

76. BarbasCF3rd, ColletTA, AmbergW, RobenP, BinleyJM, et al. (1993) Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 230: 812–823.

77. KongL, LeeJH, DooresKJ, MurinCD, JulienJP, et al. (2013) Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 20: 796–803.

78. WuX, YangZY, LiY, HogerkorpCM (2010) Schief WR, et al (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856–861.

79. PantophletR, Aguilar-SinoRO, WrinT, CavaciniLA, BurtonDR (2007) Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 364: 441–453.

80. ThaliM, MooreJP, FurmanC, CharlesM, HoDD, et al. (1993) Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67: 3978–3988.

81. TrkolaA, PurtscherM, MusterT, BallaunC, BuchacherA, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100–1108.

82. ConleyAJ, GornyMK, KesslerJA2nd, BootsLJ, Ossorio-CastroM, et al. (1994) Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol 68: 6994–7000.

83. GalloSA, SackettK, RawatSS, ShaiY, BlumenthalR (2004) The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Biol 340: 9–14.

84. ReevesPJ, CallewaertN, ContrerasR, KhoranaHG (2002) Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci U S A 99: 13419–13424.

85. NarayanKM, AgrawalN, DuSX, MuranakaJE, BauerK, et al. (2013) Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate. PLoS One 8: e52732.